Fertility-sparing tx feasible in early endometrial cancer

Fertility-sparing tx feasible in early endometrial cancer
For women with early-stage endometrial cancer and atypical complex hyperplasia, fertility-sparing treatment seems feasible, according to research published in the October issue of the American Journal of Obstetrics & Gynecology.

(HealthDay)—For women with early-stage endometrial cancer (EC) and atypical complex hyperplasia (ACH), fertility-sparing treatment seems feasible, according to research published in the October issue of the American Journal of Obstetrics & Gynecology.

Ioannis D. Gallos, M.D., from the Birmingham Women's Hospital in the United Kingdom, and colleagues conducted a systematic review and meta-analysis to examine the regression, relapse, and live birth rates for women with EC and ACH who underwent fertility-sparing treatment. A total of 34 observational studies, involving 408 women with EC and 151 women with ACH were included.

The researchers found that, for EC, fertility-sparing treatment achieved a pooled regression rate of 76.2 percent, a relapse rate of 40.6 percent, and a live birth rate of 28 percent. The corresponding figures for ACH were 85.6, 26, and 26.3 percent. During follow-up, 3.6 percent of women were diagnosed with ovarian (concurrent or metastatic), 1.9 percent of women (10 women) progressed to disease higher than stage I EC, and two of these 10 died.

"In conclusion, this review of observational studies found a high chance of disease regression and encouraging live birth rates of early-stage EC and ACH with fertility-sparing treatment followed by assisted reproduction," the authors write. "Our systematic examination of the published literature confirms that there is only moderate-quality observational evidence to inform clinical practice, and results should be interpreted with caution."

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Confusion about emergency contraception access common

date Mar 26, 2012

(HealthDay) -- While most pharmacies report having emergency contraception (EC) in stock, misinformation regarding what age women can take it without a prescription is common, according to a study published ...

ART live-birth rates can approach natural fecundity

date Jun 28, 2012

(HealthDay) -- During assisted reproductive technology, increasing maternal age and number of cycles is linked to lower live-birth rates with the use of autologous oocytes, but not donor oocytes, according ...

Recommended for you

Experts set strategic priorities for lymphoma research

date 17 hours ago

A committee of lymphoma experts today unveiled a strategic roadmap identifying key priority areas in both infrastructure and research that will be critical for advancing treatments for people with lymphoma. The report is meant to inform future research directions as well as fund ...

Research aims to reduce health care disparities

date 17 hours ago

The lesbian, gay, bisexual, transgender/transsexual, queer/questioning and intersex (LGBTQI) population has been largely understudied by the medical community. Researchers at Moffitt Cancer Center found that the LGBTQI community ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.